Evidence map›Paper›PMID 37859713›Full record

ArticleRSC medicinal chemistry2023

Design, synthesis, electrochemistry and anti-trypanosomatid hit/lead identification of nitrofuranylazines.

Maryna Saayman, Christina Kannigadu, Janine Aucamp, Helena D Janse van Rensburg, Cassiem Joseph, Andrew J Swarts, David D N'Da

Open access · hybridAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 14 citations in OpenAlex.

  1. Drug Repurposing for Kala-Azar.Pharmaceutics · 2025
    Article
  2. Exploring Thiophene Derivatives: Synthesis Strategies and Biological Significance.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2025
    Review
  3. ACS omega · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Maryna SaaymanCentre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa David.Nda@nwu.ac.za +27 18 299 4243 +27 18 299 2256.
Christina KannigaduCentre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa David.Nda@nwu.ac.za +27 18 299 4243 +27 18 299 2256.
Janine AucampCentre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa David.Nda@nwu.ac.za +27 18 299 4243 +27 18 299 2256.
Helena D Janse van RensburgCentre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa David.Nda@nwu.ac.za +27 18 299 4243 +27 18 299 2256.
Cassiem JosephMolecular Sciences Institute, School of Chemistry, University of the Witwatersrand Johannesburg-Braamfontein 2050 South Africa.ORCID https://orcid.org/0000-0003-1732-5592
Andrew J SwartsMolecular Sciences Institute, School of Chemistry, University of the Witwatersrand Johannesburg-Braamfontein 2050 South Africa.ORCID https://orcid.org/0000-0002-7942-8557
David D N'DaCentre of Excellence for Pharmaceutical Sciences, North-West University Potchefstroom 2520 South Africa David.Nda@nwu.ac.za +27 18 299 4243 +27 18 299 2256.ORCID https://orcid.org/0000-0002-2327-0551
University of the Witwatersrand · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chagas disease and leishmaniasis are vector-borne infectious diseases affecting both humans and animals. These neglected tropical diseases can be fatal if not treated. Hundreds to thousands of new Chagas disease and leishmaniasis cases are being reported by the WHO every year, and currently available treatments are insufficient. Severe adverse effects, impractical administrations and increased pathogen resistance against current clinical treatments underscore a serious need for the development of new drugs to curb these ailments. In search for such drugs, we investigated a series of nitrofuran-based azine derivatives. Herein, we report the design, synthesis, electrochemistry, and biological activity of these derivatives against promastigotes and amastigotes of

Identifiers

PMID37859713
PMCPMC10583827
OpenAlexW4385884148

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.